Invesco Dorsey Wright Healthcare Momentum ETF

Mondrian Investment Partners LLC Increased Holdings in HCA Healthcare, Inc.

Truist Financial Analyst Maintains Buy Rating on Tenet Healthcare

Axsome Therap to Release FY2025 Q4 Earnings on February 23, 2026 Pre-Market EST, Forecast Revenue USD 192.82 M, EPS USD -0.6906

Roivant Sciences Director Daniel Allen Gold Disposes of Common Stock

HCA Healthcare Executives Dispose of Common Stock

HC Wainwright Downgrades Arrowhead Pharmaceuticals Earnings Estimate

Guardant Health to release FY2025 Q4 earnings on February 19 After-Market EST, forecast revenue USD 271.77 M, EPS USD -0.7722

Praxis Precision Medicines to Release FY2025 Q4 Earnings on February 19, Pre-Market EST; Forecast Revenue USD 256.09K, EPS USD -3.1009

Tenet Healthcare released FY2025 earnings on February 11 Pre-Market EST, actual revenue USD 21.31 B (forecast USD 21.27 B), actual EPS USD 15.49 (forecast USD 15.4466)

Tenet Healthcare released FY2025 Q4 earnings on February 11 Pre-Market EST, forecasted revenue USD 5.472 B, forecasted EPS USD 3.96

Tenet Healthcare Reports Q4 Earnings and Outlines 2023 Outlook

HCA Healthcare Inc. reports 17.8% increase in net income for fiscal year 2025

Roivant Sciences released FY2026 Q3 earnings on February 6 Pre-Market (EST), actual revenue USD 1.999 M (forecast USD 6.139 M), actual EPS USD -0.3815 (forecast USD -0.31)

Roivant Sciences released FY2026 9 Months Earnings on February 6 Pre-Market EST, with actual revenue of USD 5.74 M and EPS of USD -0.8815

ArrowHead Pharma released FY2026 Q1 earnings on February 5 After-Market EST, actual revenue USD 264.03 M (forecast USD 230.85 M), actual EPS USD 0.22 (forecast USD -0.1455)

HCA Healthcare CEO Reports Disposition of Common Stock

Arrowhead Pharmaceuticals Reports Q1 2026 Revenue of $264 Million, Exceeding Estimates

Arrowhead Pharmaceuticals Reports Q1 Financial Results

Tenet Healthcare to release FY2025 Q4 earnings on February 11, 2026 Pre-Market EST, forecast revenue USD 5.472 B, EPS USD 3.9785

Tenet Healthcare Acquires 23.8% of Conifer in a $2.65B Transaction to Boost Cash Flow

Polaryx Therapeutics

Globavend

Baird Medical Investment

Leifras

Compass Pathways

GraniteShares 2x Long ETOR Daily ETF

Gaxos.ai

Masimo

Atomera

INSM

SBIO

ARKG

Roth MKM analyst Adam Walsh has maintained a Buy rating on Insmed (INSM) with a price target of $212.00. Walsh, a 3-star analyst with a 43.81% success rate, focuses on the Healthcare sector. Insmed also received a Buy rating from Goldman Sachs’s Andrea Newkirk on February 11, while TipRanks reiterated a Hold rating on February 3.

Tip Ranks

Insmed

SPDR S&P Biotech

Health Care Select Sector SPDR

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

Proshares Ultra Nasdaq Biotech

VanEck Biotech ETF

BNY Mellon Innovators ETF

iShares US Pharma

VG Health

First Trust NYSE Arca Biotech Index Fd

Ark Genomic Revolution ETF

iShares Biotechnology ETF

Roth MKM Sticks to Their Buy Rating for Insmed (INSM)

Insmed Incorporated (Nasdaq: INSM) announced its participation in two upcoming investor conferences: the 46th Annual TD Cowen Healthcare Conference in Boston on March 2, 2026, and the Leerink Partners Global Healthcare Conference in Miami on March 10, 2026. Both events will be webcast live and archived for 30 days. Insmed focuses on developing therapies for serious diseases, particularly in pulmonary and inflammatory conditions, and has been recognized as a top employer in the biopharmaceutical industry.

StockTitan

iShares Global Healthcare

Insmed To Present at March 2026 Investor Conferences | INSM Stock News

INSMED's Chair and CEO, William Lewis, sold 13,396 shares of common stock on February 9, 2026, under a 10b5-1 trading plan, totaling $1,979,763. The shares were sold at average prices of $147.17, $148.02, and $148.83. Post-sale, Lewis holds 301,185 shares directly and 284,424 shares indirectly through trusts.

TradingView

INSMED Chair and CEO William Lewis Sells 13,396 Shares

Wellington Shields Capital Management LLC invested $1.22 million in Insmed, Inc. by acquiring 8,472 shares in the 3rd quarter. Other institutional investors also increased their stakes in the biopharmaceutical company. Analysts have set various price targets for Insmed, with a consensus rating of "Buy" and an average target price of $203.45. Insmed's stock performance shows a market cap of $31.96 billion and a price-to-earnings ratio of -24.21. Recent insider sales were reported, with insiders owning 3.00% of the company's stock.

Market Beat

Wellington Shields Capital Management LLC Invests $1.22 Million in Insmed, Inc. $INSM

Martina Flammer, M.D., Chief Medical Officer of Insmed Inc., reported the disposal of common shares of the company. The full filing is accessible via the provided link. This news was generated by Public Technologies and is for informational purposes only, not to be considered as financial, investment, or legal advice. Insmed Inc. is responsible for the original content published through EDGAR on February 06, 2026.

Reuters

Insmed Chief Medical Officer Martina Flammer Reports Disposal of Common Shares

Senior executives at Insmed (INSM) have engaged in a coordinated stock sale, with CEO William Lewis leading the transactions. Collectively, they sold over 5,000 shares, raising concerns of profit-taking after the stock nearly doubled in the past year. Despite this, INSM stock has dropped 12% in 2026 following the halt of a drug development. Analysts maintain a consensus Strong Buy rating for Insmed, with an average price target suggesting a 44.10% upside from current levels.

Insmed (INSM) Executives Engage in Coordinated Stock Sale

Insmed shares are trading lower after the company announced it will present four abstracts on treprostinil palmitil inhalation powder at PVRI 2026 congress in Dublin. Barclays initiated coverage on the stock with an Overweight rating and announced a $231 price target.

benzinga_article

Direxion S&P Biotech Bear 3X

Insmed reported strong preliminary 2025 results with total revenue rising to $606.4 million, driven by ARIKAYCE and BRINSUPRI sales. The company outlined a 2026 roadmap, including an EU launch for BRINSUPRI and late-stage clinical trials. While the revenue guidance supports growth, concerns about persistent losses and shareholder dilution remain. Analysts have varying fair value estimates for Insmed, highlighting differing views on its potential. Investors are encouraged to consider both opportunities and risks in their investment narrative.

Simplywall

Did Insmed’s (INSM) ARIKAYCE and BRINSUPRI Surge Just Recast Its Investment Narrative?

During the last three months, 18 analysts evaluated Insmed (NASDAQ:INSM), showing a range of bullish to bearish sentiments. The average 12-month price target is $226.22, up 7.67% from the previous target. Analysts have adjusted their ratings, with some raising and others lowering their price targets. Insmed's market capitalization is below industry average, but it achieved a 52.36% revenue growth rate. However, its net margin is -259.95%, and ROE and ROA are below industry averages, indicating challenges in financial returns. Insmed is a biopharmaceutical company focused on serious diseases.

Breaking Down Insmed: 18 Analysts Share Their Views

Invesco Dorsey Wright Healthcare Momentum ETF(PTH.US)

Roth MKM Sticks to Their Buy Rating for Insmed (INSM)

Insmed To Present at March 2026 Investor Conferences | INSM Stock News

INSMED Chair and CEO William Lewis Sells 13,396 Shares

Wellington Shields Capital Management LLC Invests $1.22 Million in Insmed, Inc. $INSM

Insmed Chief Medical Officer Martina Flammer Reports Disposal of Common Shares